Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 2/20 | 0.56 |
| ▸ | CRHR1 | P34998 | 10/20 | 0.48 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.48 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.48 |
| ▸ | ASPH | Q12797 | 2/20 | 0.47 |
| ▸ | KDM8 | Q8N371 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | RIOX2 | Q8IUF8 | 1/20 | 0.47 |
| ▸ | DHODH | Q02127 | 1/20 | 0.44 |
| ▸ | LIPC | P11150 | 1/20 | 0.42 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3576127 | 0.79 | DHODH (0.48) | MCHR1KDM4EDHODH | |
| SCHEMBL9261169 | 0.78 | DHODH (0.47) | MCHR1DHODH | |
| SCHEMBL3573045 | 0.78 | MCHR1 (0.49) | MCHR1CRHR1DHODHTDP1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL9251146 | 0.75 | CHRNA7 (0.46) | MCHR1KDM4CKDM4EDHODH | |
| SCHEMBL15635184 | 0.75 | DHODH (0.48) | MCHR1KDM4CASPHKDM8KDM4E | |
| SCHEMBL17363149 | 0.75 | MCHR1 (0.56) | MCHR1DHODHL3MBTL1 | |
| SCHEMBL15635615 | 0.75 | DHODH (0.48) | MCHR1DHODHL3MBTL1 | |
| SCHEMBL496596 | 0.74 | KDM4C (0.54) | KDM4CASPHKDM8KDM4EDHODH | |
| SCHEMBL1397722 | 0.73 | DHODH (0.51) | KDM4CKDM4EDHODHTDP1L3MBTL1 | |
| SCHEMBL15639577 | 0.73 | DHODH (0.46) | MCHR1DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1955697-B1 | 2-AMINOBENZAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) INHIBITORS USEFUL FOR THE TREATMENT OF PAIN OR BLADDER FUNCTION DISORDER | ASTELLAS PHARMA INC (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-8106190-B2 | 2-aminobenzamide derivatives | ASTELLAS PHARMA INC. (JP) | 2012-01-31 | — | — | US | disclosed |
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1955697-A1 | 2-AMINOBENZAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | TRPV1, TRPV2, TRPV5 | MCHR1 1114/4885CRHR1 1035/4885CRHR2 889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.